The company incurred a net loss of $6.6 million, or a loss per share of $0.39, compared to a net loss of $6.5 million, or a loss per share of $0.40, in the year-ago quarter. Street analysts expected a loss per share of $0.35.
OncoSec disclosed that it continued to develop its lead clinical program, ImmunoPulse IL-12, meant for anti-PD1 non-responsive patient in melanoma. The company revealed that the program is progressing well offering a possible immunotherapy.
The company's president and CEO, Punit Dhillon, stated, "Subject to these interim results and discussions with the U.S. Food and Drug Administration, we expect to submit a registration directed study design for ImmunoPulse® IL-12 by the end of 2016."
OncoSec indicated that it would continue to expand its research pipeline while widening the scope for its engineering efforts for fresh devices. The company expects to launch the new device along with its next clinical candidate.
The stock closed at $1.74 on Thursday's regular trading. At last check in Friday's morning session, OncoSec was down 2.29 percent at $1.70.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
